Biohit Oyj - Notice to general meeting

NOTICE OF BIOHIT OYJ'S ANNUAL GENERAL MEETING

Biohit Oyj  Stock exchange release      16.3.2012     5.45 pm

Biohit Oyj shareholders are invited to attend the company's Annual General
Meeting, which will be held at Hotel Royal at Crowne Plaza, conference room 2,
Mannerheimintie 50, 00260 Helsinki, on 11 April 2012, starting at 3:00 pm. 

The reception of shareholders registered for the meeting and the distribution
of voting slips will commence at 1:30 pm. 


A. Matters on the agenda of the Annual General Meeting

The following matters will be presented for consideration at the Annual General
Meeting: 

1. Opening of the meeting

2. Calling the meeting to order

3. Election of persons to scrutinise the minutes and supervise the counting of
votes 

4. Recording the attendance at the meeting and the list of votes

5. Recording the legality of the meeting

6. Presentation of the Financial Statements, the Report of the Board of
Directors and Auditors' Report for 2011, and the CEO's review 

7. Adoption of the Financial Statements

8. Resolution on the use of the result shown on the Balance Sheet and on
dividend payment 

The Board of Directors proposes that the profit for the financial period ended
on 31 December 2011 be recorded in the profit and loss account. 

The Board of Directors proposes that on the basis of the financial statements
to be adopted for the financial period ended on 31 December 2011, a dividend of
EUR 0.1973 per each A share and EUR 0,2007 for each B share be paid. Dividend
will be paid to shareholders recorded in the company's shareholder register on
the matching day, 16 April 2012. The Board of Directors proposes that the
dividend will be paid out on 23 April 2012. 

9. Distribution of funds from the invested non-restricted equity fund

The Board of Directors proposes that on the basis of the financial statements
to be adopted for the financial period ended on 31 December 2011, funds from
the invested non-restricted equity fund be distributed to shareholders as a
capital repayment, with the capital repaid amounting to EUR 0.80 for each A and
B share. Capital will be repaid to shareholders recorded in the company's
shareholder register on the repayment day, 16 April 2012. The Board of
Directors proposes that the capital repayment will be made on 23 April 2012. 

10. Resolution on the discharge of the members of the Board of Directors and
the CEO from liability 

11. Resolution on the number and remuneration of the members of the Board of
Directors 

Shareholders representing more than 50% of the voting rights conferred by all
Biohit's shares have announced their intention to propose to the Annual General
Meeting that the number of Board members be confirmed at seven (7). These
shareholders have announced their intention to propose to the Annual General
Meeting that the following monthly remuneration be paid to the Board members
and the Chairman: EUR 1,600 to the Chairman and EUR 1500 to other Board
members. 

12. Election of Board members

Shareholders representing more than 50% of the voting rights conferred by all
Biohit's shares have announced their intention to propose to the Annual General
Meeting that the following  Board members be re-elected until the end of the
next AGM: Kalle Kettunen, M.Sc.Eng., Osmo Suovaniemi, professor, Mikko
Salaspuro, professor, Eero Lehti, Petteri Kilpinen, CEO, Seppo Luode,
M.Sc.Eng., and Saila Miettinen-Lähde, CFO. More information on member
candidates is available on the company website at
www.biohit.healthcare.com/investors 

13. Resolution on the remuneration of the Auditor

The Board of Directors proposes that the Auditor to be elected be remunerated
in accordance with his/her invoice. 

14. Election of the Auditor

Shareholders representing more than 50% of the voting rights conferred by all
Biohit's shares have announced their intention to propose that Authorised
Public Accountants Ernst & Young Oy be elected as Auditors until the end of the
next AGM. 

15. Closing of the meeting


B. Documents for the General Meeting

The above proposals of the Board of Directors [and shareholders], included in
the agenda of the Annual General Meeting, as well as this notice, are available
on Biohit Oyj's website at www.biohithealthcare.com/investors 

The Financial Statements, Consolidated Financial Statements, the Report of the
Board of Directors of Biohit Oyj and the Auditor's Report are available on the
above website and at the company's headquarters Laippatie 1, 00880 Helsinki. 

The Board's and shareholders' proposals and Financial Statements will also be
available at the Annual General Meeting, and copies of them and of this notice
will be sent to shareholders by request. 


C. Instructions for the participants at the Annual General Meeting

1. The right to participate and registration

Shareholders who on the Annual General Meeting record date of 28 March 2012 are
registered in the shareholder register maintained by Euroclear Finland Oy have
the right to participate in the Annual General Meeting. Any shareholder whose
shares are registered on his/her personal Finnish book-entry account is
registered in the company's shareholder register. 

Shareholders wishing to participate in the Annual General Meeting must register
their participation. Registration begins on 19 March 2012 at 10:00 am and ends
on 4 April 2012 at 4:00 pm. 

Registration may be submitted:
- Online at  www.biohithealthcare.com/investors
- By e-mail: yhtiokokous@biohit.fi
- By telephone: +358 9 773 861
- By letter: Biohit Oy, Yhtiökokous, Laippatie 1, 00880 Helsinki

When registering for the meeting, the following details shall be provided: the
shareholder's name, personal identity number, address and telephone number as
well as the name of any proxy representative or assistant to be used, and the
personal identity number of the assistant. The personal data given by
shareholders to Biohit Oyj will only be used in connection with the General
Meeting and for processing the necessary registrations. 

Pursuant to Chapter 5, section 25 of the Limited Liabilities Companies Act, a
shareholder who is present at the General Meeting has the right to request
information with respect to the matters to be considered at the meeting. 

2. 2. Proxy representatives and powers of attorney

A shareholder may participate in the General Meeting and exercise his/her
rights at the meeting through proxy representation. A shareholder may have
several proxy representatives representing the shareholder with shares in
different securities accounts. In such a case, the shares with which each proxy
representative represents the shareholder shall be specified at the time of
registration. 

A proxy representative shall produce a dated proxy document or otherwise
demonstrate, in a reliable manner, his/her right to represent the shareholder
at the meeting. Any proxy documents should be delivered as originals no later
than 10:00 am on 4 April 2012 to Biohit Oyj, Yhtiökokous, Laippatie 1, 00880
Helsinki. 

3. Holders of nominee registered shares

If a holder of nominee registered shares is entitled to be registered in the
company's shareholder register on the record date of 28 March 2012, the
shareholder may, in accordance with instructions from his/her asset manager,
ask to be temporarily entered into the company's shareholder register for
participation in the General Meeting on 4 April 2012 at 16:00 am at the latest.
The holder of nominee registered shares is deemed to have registered for the
General Meeting if he/she was registered for a temporary entry in the
shareholder register in the manner described above. 

A holder of nominee registered shares is advised to request from his/her asset
manager to provide the necessary instructions for temporary registration in the
company's shareholder register, the issuing of proxy documents and registration
for the General Meeting. 

4. Other information

On 16 March 2012, the date of the notice of the AGM, the share capital of
Biohit Oyj consists of a total of 13,615,593 shares. The shares are divided
into Series A and Series B. The total number of Series A shares is 2,975,500,
producing a total of 59,510,000 votes, while the total number of Series B is
10,640,093, producing a total of 10,640,093 votes. 

Helsinki, 16 March 2012


Biohit Oyj
Board of Directors